New York State Teachers Retirement System Has $1.24 Million Stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

New York State Teachers Retirement System lowered its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 2.2% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 30,884 shares of the company’s stock after selling 698 shares during the period. New York State Teachers Retirement System owned approximately 0.05% of Harmony Biosciences worth $1,235,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Hedeker Wealth LLC lifted its position in shares of Harmony Biosciences by 3.7% during the 3rd quarter. Hedeker Wealth LLC now owns 75,287 shares of the company’s stock worth $3,011,000 after buying an additional 2,662 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Harmony Biosciences by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,931 shares of the company’s stock worth $437,000 after buying an additional 4,259 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Harmony Biosciences by 8,867.7% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,560 shares of the company’s stock worth $222,000 after buying an additional 5,498 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Harmony Biosciences by 21.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company’s stock worth $80,000 after buying an additional 360 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its position in shares of Harmony Biosciences by 20.8% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 54,274 shares of the company’s stock worth $2,171,000 after buying an additional 9,329 shares in the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Insider Activity

In other news, insider Jeffrey Dierks sold 21,496 shares of the business’s stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total transaction of $869,943.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 30.80% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on HRMY. Needham & Company LLC reissued a “buy” rating and set a $52.00 target price on shares of Harmony Biosciences in a research report on Tuesday, October 29th. Cantor Fitzgerald lifted their target price on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Oppenheimer reissued an “outperform” rating and set a $59.00 target price (up previously from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Raymond James reaffirmed an “outperform” rating and issued a $40.00 price target on shares of Harmony Biosciences in a report on Thursday, October 10th. Finally, UBS Group started coverage on shares of Harmony Biosciences in a report on Tuesday, September 10th. They issued a “buy” rating and a $56.00 price target on the stock. Two investment analysts have rated the stock with a sell rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.

Harmony Biosciences Trading Up 3.4 %

Shares of HRMY stock opened at $36.08 on Friday. The company’s fifty day simple moving average is $36.15 and its two-hundred day simple moving average is $33.33. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. Harmony Biosciences Holdings, Inc. has a 1 year low of $22.89 and a 1 year high of $41.61. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of 17.10, a PEG ratio of 0.64 and a beta of 0.77.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15. The business had revenue of $186.00 million for the quarter, compared to analysts’ expectations of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business’s revenue for the quarter was up 16.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.63 EPS. As a group, analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.36 earnings per share for the current year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.